Enovis Co. (NYSE:ENOV) Receives $75.43 Average Price Target from Analysts

Enovis Co. (NYSE:ENOV) has earned an average recommendation of “Buy” from the eight ratings firms that are covering the company, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $75.43.

Several research analysts recently issued reports on ENOV shares. Stephens assumed coverage on Enovis in a research report on Tuesday, February 13th. They set an “overweight” rating and a $72.00 price objective for the company. William Blair began coverage on Enovis in a report on Wednesday, January 3rd. They issued an “outperform” rating for the company. Wells Fargo & Company upped their price objective on Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. UBS Group started coverage on shares of Enovis in a research note on Monday, January 22nd. They issued a “buy” rating and a $75.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $82.00 target price on shares of Enovis in a report on Wednesday, April 10th.

Enovis Stock Down 3.0 %

Enovis stock opened at $56.82 on Tuesday. Enovis has a fifty-two week low of $43.04 and a fifty-two week high of $66.14. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -93.15 and a beta of 1.97. The stock’s fifty day moving average is $60.61 and its two-hundred day moving average is $55.26. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.16 and a current ratio of 2.43.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.76 by $0.03. The firm had revenue of $455.00 million for the quarter, compared to analysts’ expectations of $444.34 million. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. The firm’s revenue was up 11.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.72 EPS. Analysts predict that Enovis will post 2.58 EPS for the current fiscal year.

Institutional Trading of Enovis

Hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio lifted its stake in shares of Enovis by 48.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 65,916 shares of the company’s stock valued at $3,476,000 after purchasing an additional 21,479 shares in the last quarter. Tributary Capital Management LLC grew its stake in shares of Enovis by 14.9% in the fourth quarter. Tributary Capital Management LLC now owns 292,626 shares of the company’s stock valued at $16,393,000 after buying an additional 37,858 shares in the last quarter. Lawson Kroeker Investment Management Inc. NE purchased a new stake in shares of Enovis during the 4th quarter valued at about $7,013,000. GSA Capital Partners LLP acquired a new position in Enovis during the 3rd quarter worth approximately $1,339,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Enovis by 174.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 7,688 shares of the company’s stock worth $405,000 after acquiring an additional 4,886 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.